NASDAQ:PRPO Precipio (PRPO) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free PRPO Stock Alerts $6.15 -0.18 (-2.84%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$6.06▼$6.2950-Day Range$6.00▼$6.8452-Week Range$4.75▼$14.80Volume3,618 shsAverage Volume4,197 shsMarket Capitalization$8.79 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Precipio alerts: Email Address Precipio MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside550.4% Upside$40.00 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.34 out of 5 stars 2.0 Analyst's Opinion Amount of Analyst CoveragePrecipio has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.39% of the float of Precipio has been sold short.Short Interest Ratio / Days to CoverPrecipio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precipio has recently increased by 6.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecipio does not currently pay a dividend.Dividend GrowthPrecipio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPO. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Precipio this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precipio insiders have not sold or bought any company stock.Percentage Held by Insiders10.60% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.45% of the stock of Precipio is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Precipio is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precipio is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecipio has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Tips4TradersUncover this 2024 Hidden GemExclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.[Click here to subscribe] and elevate your trading today. About Precipio Stock (NASDAQ:PRPO)Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.Read More PRPO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRPO Stock News HeadlinesApril 24, 2024 | americanbankingnews.comPrecipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.64April 20, 2024 | finance.yahoo.comPrecipio, Inc. (PRPO) Latest Stock News & Headlines - Yahoo FinanceApril 24, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 19, 2024 | morningstar.comPrecipio Inc PRPOApril 16, 2024 | americanbankingnews.comPrecipio (NASDAQ:PRPO) Stock Price Crosses Below 200-Day Moving Average of $6.62March 25, 2024 | globenewswire.comPrecipio Announces Year end 2023 Shareholder Update CallMarch 12, 2024 | ca.finance.yahoo.comPrecipio, Inc. (PRPO)February 23, 2024 | benzinga.comPrecipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, PredictionsApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 13, 2024 | finance.yahoo.comPrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYFebruary 6, 2024 | finanznachrichten.dePrecipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for CancerJanuary 23, 2024 | msn.comPrecipio’s Q4 cash burn from operations drops below $100K for full quarterJanuary 23, 2024 | finanznachrichten.dePrecipio, Inc.: Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterJanuary 23, 2024 | finance.yahoo.comPrecipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterJanuary 17, 2024 | finanznachrichten.dePrecipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in JapanJanuary 17, 2024 | finance.yahoo.comPrecipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanJanuary 2, 2024 | finance.yahoo.comPrecipio Announces Christina Valauri joins the Board of DirectorsDecember 15, 2023 | finanznachrichten.dePrecipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024December 14, 2023 | finance.yahoo.comPrecipio Management Shares Thoughts on 2023, and Looks Ahead To 2024October 18, 2023 | finance.yahoo.comPrecipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022October 3, 2023 | finanznachrichten.dePrecipio, Inc.: Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023October 3, 2023 | finance.yahoo.comPrecipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023September 28, 2023 | finance.yahoo.comPrecipio Continues to Sign New HemeScreen™ CustomersSeptember 25, 2023 | finance.yahoo.comPrecipio Reduces Product Revenue Result Needed for Cash Flow BreakevenSeptember 22, 2023 | finanznachrichten.dePrecipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq ComplianceSeptember 13, 2023 | finance.yahoo.comPrecipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of PlanAugust 20, 2023 | finance.yahoo.comBroker Revenue Forecasts For Precipio, Inc. (NASDAQ:PRPO) Are Surging HigherSee More Headlines Receive PRPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/23/2018Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:PRPO CUSIPN/A CIK1043961 Webwww.precipiodx.com Phone(203) 787-7888Fax402-452-5401Employees51Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+550.4%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($4.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,850,000.00 Net Margins-38.51% Pretax Margin-38.51% Return on Equity-51.75% Return on Assets-37.93% Debt Debt-to-Equity Ratio0.01 Current Ratio1.17 Quick Ratio1.05 Sales & Book Value Annual Sales$15.20 million Price / Sales0.58 Cash FlowN/A Price / Cash FlowN/A Book Value$10.16 per share Price / Book0.61Miscellaneous Outstanding Shares1,430,000Free Float1,278,000Market Cap$8.79 million OptionableOptionable Beta1.61 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Ilan Danieli (Age 52)Founder, President, CEO & Director Comp: $324.1kDr. Ayman A. Mohamed M.D. (Age 39)Chief Technology Officer Comp: $234.1kMr. Matthew Gage (Age 57)Chief Financial Officer Mr. Ahmed Zaki Sabet (Age 37)Chief Operating Officer Comp: $229.03kMs. Miri Chiko-RadomskiChief Legal Counsel & People OfficerKey CompetitorsTelesis BioNASDAQ:TBIOTalis BiomedicalNASDAQ:TLISAccelerate DiagnosticsNASDAQ:AXDXCue HealthNASDAQ:HLTHSingular Genomics SystemsNASDAQ:OMICView All Competitors PRPO Stock Analysis - Frequently Asked Questions What is Precipio's stock price target for 2024? 0 brokerages have issued 1 year price targets for Precipio's stock. Their PRPO share price targets range from $40.00 to $40.00. On average, they predict the company's share price to reach $40.00 in the next year. This suggests a possible upside of 550.4% from the stock's current price. View analysts price targets for PRPO or view top-rated stocks among Wall Street analysts. How have PRPO shares performed in 2024? Precipio's stock was trading at $6.50 at the beginning of 2024. Since then, PRPO stock has decreased by 5.4% and is now trading at $6.15. View the best growth stocks for 2024 here. When is Precipio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our PRPO earnings forecast. How were Precipio's earnings last quarter? Precipio, Inc. (NASDAQ:PRPO) posted its quarterly earnings results on Thursday, August, 23rd. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of $38.60 by $41.60. The biotechnology company had revenue of $0.82 million for the quarter. Precipio had a negative net margin of 38.51% and a negative trailing twelve-month return on equity of 51.75%. When did Precipio's stock split? Precipio shares reverse split before market open on Friday, September 22nd 2023. The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Precipio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Jaguar Health (JAGX). How do I buy shares of Precipio? Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRPO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingPrepare for a recession unlike any otherAmerican Hartford Gold GroupExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precipio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
